ArticlemAbs2025
Paratope plasticity determines anti-HER2 (4B5) antibody specificity.
Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody immunohistochemistry (IHC) assay is used to identify patients eligible for anti-HER2 targeted therapy. Previous work has demonstrated that the 4B5 antibody can react with the related family member HER4, and the nuclear protein ZSCAN18, under experimental conditions. Here, we used surface plasmon resonance, automated capillary electrophoresis (ACE), and IHC to fully define the 4B5 epitope and binding characteristics. The key amino acids that contribute to antibody recognition were identified and characterized with the limits of detection determined for HER4 and ZSCAN18. Additionally, the protein target responsible for cytoplasmic and nuclear reactivity observed by 4B5 in non-breast tissue types, that is not attributable to either HER2, HER4, or ZSCAN18, was identified. By means of protein purification, mass spectrometry, ACE analysis and IHC, 4B5 was found to react with the cytosolic aldo-keto reductase family 1 members B1, B10 and B15 (AKR1B1, AKR1B10, AKR1B15). The binding characteristics and limits of detection for these off-target species were defined. In-silico docking analysis of computationally folded 4B5 paratope regions identified key differences in the 4B5 paratope interaction between a peptide containing the HER2 epitope versus that of a partially homologous peptide sequence common to the AKR1 family. Flexibility of the complementarity-determining region loops in 4B5 imparts paratope plasticity that enables interaction with AKR1B family proteins. This antibody off-target recognition can result in cytoplasmic and nuclear IHC staining.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.